2020
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM, Chiocca EA, Cloughesy TF, DeGroot JF, Galanis E, Gilbert MR, Hegi ME, Horbinski C, Huang RY, Lassman AB, Le Rhun E, Lim M, Mehta MP, Mellinghoff IK, Minniti G, Nathanson D, Platten M, Preusser M, Roth P, Sanson M, Schiff D, Short SC, Taphoorn MJB, Tonn JC, Tsang J, Verhaak RGW, von Deimling A, Wick W, Zadeh G, Reardon DA, Aldape KD, van den Bent MJ. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology 2020, 22: 1073-1113. PMID: 32328653, PMCID: PMC7594557, DOI: 10.1093/neuonc/noaa106.Peer-Reviewed Original ResearchConceptsNeuro-oncologyConsensus reviewCurrent managementMalignant primary brain tumorIsocitrate dehydrogenase-wildtype glioblastomaPrimary brain tumorsNovel therapiesViral therapyBrain tumorsImportant causeMolecular pathogenesisMolecular therapyEuropean AssociationTherapyEuropean SocietyCommon formGlioblastomaWildtype glioblastomaTumorsFuture directionsImportant advancesImmunotherapyMorbidityPatientsDNA damage response
2019
DNMT3A co-mutation in an IDH1-mutant glioblastoma
Fomchenko EI, Erson-Omay EZ, Zhao A, Bindra RS, Huttner A, Fulbright RK, Moliterno J. DNMT3A co-mutation in an IDH1-mutant glioblastoma. Molecular Case Studies 2019, 5: a004119. PMID: 31371348, PMCID: PMC6672028, DOI: 10.1101/mcs.a004119.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkers, TumorBrain NeoplasmsDNA (Cytosine-5-)-MethyltransferasesDNA MethylationDNA Methyltransferase 3ADNA Modification MethylasesEpigenesis, GeneticGene Expression ProfilingGene Expression Regulation, NeoplasticGlioblastomaGliomaHumansIsocitrate DehydrogenaseMaleMutationMutation, MissensePromoter Regions, GeneticConceptsIDH1-mutant glioblastomaEpigenetic controlHistone modificationsTranscriptional regulationDNA methylationExpression profilesGlioblastoma biologySomatic mutationsDe novoMutationsMutant glioblastomasTumor landscapeMutational profileTargeted therapeutic approachesGlioblastomaImportant roleMethylationDNMT3ABiologyGliomagenesisMissenseRegulationNovoPrimary brain tumorsTherapeutic approachesNanoparticle-mediated intratumoral inhibition of miR-21 for improved survival in glioblastoma
Seo YE, Suh HW, Bahal R, Josowitz A, Zhang J, Song E, Cui J, Noorbakhsh S, Jackson C, Bu T, Piotrowski-Daspit A, Bindra R, Saltzman WM. Nanoparticle-mediated intratumoral inhibition of miR-21 for improved survival in glioblastoma. Biomaterials 2019, 201: 87-98. PMID: 30802686, PMCID: PMC6451656, DOI: 10.1016/j.biomaterials.2019.02.016.Peer-Reviewed Original ResearchConceptsEfficient intracellular deliveryDelivery systemPeptide nucleic acidNanoparticle productsNanoparticlesIntracellular deliveryConvection-enhanced deliveryDifferent delivery systemsNucleic acidsSignificant therapeutic efficacyMiR-21 suppressionTherapeutic efficacyLocal deliveryDeliverySystemic toxicityBlock copolymersDistinct advantagesPolyglycerolMiR-21
2017
State of the art: the evolving role of RT in combined modality therapy for GBM
Bindra RS, Galanis E, Mehta MP. State of the art: the evolving role of RT in combined modality therapy for GBM. Journal Of Neuro-Oncology 2017, 134: 477-478. PMID: 28913783, PMCID: PMC5866384, DOI: 10.1007/s11060-017-2596-4.Peer-Reviewed Original ResearchGBM radiosensitizers: dead in the water…or just the beginning?
Bindra RS, Chalmers AJ, Evans S, Dewhirst M. GBM radiosensitizers: dead in the water…or just the beginning? Journal Of Neuro-Oncology 2017, 134: 513-521. PMID: 28762004, DOI: 10.1007/s11060-017-2427-7.Peer-Reviewed Original ResearchConceptsPre-clinical evidenceNovel therapeutic approachesGBMs recurDevelopment of radiosensitizersClinical trialsTherapeutic approachesDNA damage response inhibitorsLocal controlPrimary siteDNA repair inhibitorsPotent agentOxidative stressRadiosensitizerRepair inhibitorsRadiosensitizationInhibitorsRadiotherapyClinicHypoxiaTrialsThe role of radiation in treating glioblastoma: here to stay
Corso CD, Bindra RS, Mehta MP. The role of radiation in treating glioblastoma: here to stay. Journal Of Neuro-Oncology 2017, 134: 479-485. PMID: 28271281, DOI: 10.1007/s11060-016-2348-x.Peer-Reviewed Original Research
2016
PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma
Gaudin A, Song E, King AR, Saucier-Sawyer JK, Bindra R, Desmaële D, Couvreur P, Saltzman WM. PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma. Biomaterials 2016, 105: 136-144. PMID: 27521616, PMCID: PMC5072177, DOI: 10.1016/j.biomaterials.2016.07.037.Peer-Reviewed Original ResearchConceptsConvection-enhanced deliveryGlioblastoma multiformeChemotherapeutic drugsFirst-line treatmentExtracranial solid tumorTumor-bearing animalsSurvival of animalsBrain extracellular spaceLine treatmentTumor bedIntracranial tumorsOrthotopic modelTreatment resistanceSolid tumorsGBM treatmentTherapeutic efficacyNew treatmentsTumor tissueHealthy animalsGBM prognosisFree gemcitabineMR contrast agentsNucleoside analoguesDrugsGemcitabineSuccess and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions
Corso CD, Bindra RS. Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions. Seminars In Radiation Oncology 2016, 26: 281-298. PMID: 27619250, DOI: 10.1016/j.semradonc.2016.06.003.Peer-Reviewed Original ResearchConceptsCurrent standard treatmentGlioblastoma multiformeStandard treatmentTreatment of GBMDistant brain relapseAggressive intracranial tumorBrain relapseAggressive therapyModality therapySurgical resectionCombined modalityIntracranial tumorsModality approachOncology communityTherapyMultiformeTreatmentUnanswered questionsImmunotherapyResectionRelapseFailureTumors